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ABSTRACT 
Mesenchymal stem cells (MSCs) are multipotent stromal cells which can differentiate 
into a variety of cell types including osteoblasts, adipocytes and chondrocytes. They 
are normally resident in adipose tissue, bone marrow and the umbilical cord, but can 
also be found in other tissues and are known to be recruited to sites of wound healing 
as well as growing tumours. The therapeutic potential of MSCs has been explored in 
a number of phase I/II and III clinical trials, of which several were targeted against 
graft-versus-host disease and to support engraftment of haematopoietic stem cells 
(HSCs), but currently only very few in the oncology field. There are now three clinical 
trials either ongoing or recruiting patients that use MSCs to treat tumour disease. In 
these, MSCs target gastrointestinal, lung and ovarian cancer, respectively. The first 
study uses MSCs loaded with a HSV-TK expression construct under the control of the 
CCL5 promoter, and has recently reported successful completion of Phase I/II. While 
no adverse side effects were seen during this study, no outcomes with respect to 
therapeutic benefits have been published. The other clinical trials targeting lung and 
ovarian cancer will be using MSCs expressing cytokines as therapeutic payload.  
Despite these encouraging early steps towards their clinical use, many questions are 
still unanswered regarding the biology of MSCs in normal and pathophysiological 
settings. In this review, in addition to summarising the current state of MSC-based 
therapeutic approaches for cancer, we will describe the remaining questions, obstacles 
and risks, as well as novel developments such as MSC-derived nanoghosts. 
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MSCs and their potential use in cancer treatment 
 
MSCs were first isolated and characterised by Friedenstein and his colleagues in the 
1960-1970s [1]. They are non-haematopoietic cell precursors, initially found in the 
bone marrow, but actually present in many other tissues [2]. The International Society 
of Cellular Therapy (ISCT) uses three criteria to define MSCs [3]: Firstly, MSCs can 
adhere to plastic under standard culture conditions; secondly, MSCs express cell 
surface markers including CD105, CD73 and CD90 with no expression of endothelial, 
haematopoietic, or immunological cell markers such as CD45, CD34, CD14, CD11b, 
CD79α, CD19 and HLA-DR; thirdly, MSCs have the ability to differentiate into 
osteoblasts, adipocytes, and chondroblasts when exposed to the appropriate stimuli 
[4]. MSCs can be readily transduced by a variety of vectors such as Adenovirus, 
Lentivirus and Adeno-associated virus (AAV) [5-9]. Owing to their relative immune-
privilege/-evasiveness and general immune-dampening activities, MSCs can be used 
in an allogenic setting and are therefore well suited as an off-the-shelf cell therapeutic 
agent [10, 11].  
Even though MSCs have been found in and derived from various tissues, the most 
frequently used MSCs are from bone marrow (BM-MSCs), adipose tissue (AT-MSCs) 
and umbilical cord (UC-MSCs) [12-14]. As for this good availability and the relative 
straightforward culturing conditions, MSCs gained increasingly clinical attraction 
over the last ten years including the treatment of cancer. Generally, the use of MSCs 
as cellular vehicles in the latter context is based on their ability to home to tumours as 
they are recognised by MSCs as a “wound that never heals” [15]. This tumour tropism 
is part of the normal repair function in which MSCs are recruited by sites of tissue 
injury and inflammation. They are capable of extravasating into tumours when 
introduced into the organism via the blood stream [16], and although the molecular 
mechanisms behind the migration of MSCs are still not fully understood, studies have 
shown that the migration is regulated by various cytokines and their corresponding 
receptors, i.e. SDF-1/CXCR4, HGF/c-Met, VEGF/VEGFR, PDGF/PDGFR, MCP-
1/CCR2, and HMGB1/RAGE [17]. 
In the context of such cell therapeutic approaches, MSCs are used as gene delivery 
vehicles for tumour targeted therapies. In several preclinical cancer models, MSCs 
4 
 
have been genetically modified to express cytokines, growth factor antagonists, 
antiangiogenic factors, prodrug-converting enzymes and proapoptotic proteins (Fig. 
1 and Supplementary Table 1). Another relatively early-stage approach uses MSCs as 
carrier for oncolytic viruses [18, 19]. Such modified MSCs have been used in different 
tumour type models including colon cancer [20, 21], pancreatic cancer [22-24], lung 
cancer [25-29], breast carcinoma [30-32], ovarian cancer [33], prostate cancer [34, 35], 
hepatocellular carcinoma [36-39], glioma [40-44],  melanoma [45], malignant 
mesothelioma [46] and lymphoma [47]. Although these pre-clinical studies clearly 
demonstrated therapeutic benefits of MSC-based targeted approaches, very few 
clinical trials utilising MSCs as delivery vehicles for anti-cancer treatments have been 
approved [48, 49]. This delay in transition from bench to bedside is at least in parts 
due to reports that MSCs not only display a potential to undergo malignant 
transformation, but can also lead to metastasis induction. Both of these issues embody 
possible barriers for the safe use of MSCs in cancer treatment and will be discussed 
below. 
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Potential problems with MSCs in cancer therapies 
 
Do MSCs undergo malignant transformation and form tumours? 
In the 2000s it was reported that MSCs could undergo spontaneous, malignant 
transformation and form tumours in vivo, dramatically increasing the risk of 
therapeutic use of MSCs [50-52]. However, these initial reports were subsequently 
retracted as it turned out that the observed tumour formation was the result of cross-
contaminations with cancer cells [53, 54]. In detail, the subsequent analyses showed 
that the MSC cultures were cross-contaminated with a human sarcoma cell line in one 
case, and in the second case the presence of two glioma cell lines was detected by DNA 
fingerprinting and short tandem repeat (STR) analysis [54]. These results underscore 
the need for stringent cell culture procedures when it comes to the use of primary cell 
cultures, including MSCs, for therapeutic purposes. Notwithstanding, the acquisition 
of genetic abnormalities in vitro has been observed by several groups [55-57]. 
However, despite these chromosomal abnormalities no evidence of subsequent 
malignant transformation was found in these studies [58]. More importantly, there are 
no reports on MSC-related tumour formation in human patients after MSC 
administration [59, 60]. It cannot be ruled out though, that there is still a hypothetical 
and residual risk of developing tumours after treatment with MSCs, which harboured 
cytogenetic abnormalities at the time of injection or develop them later post-
administration. Follow-up studies of patients who received MSCs as part of their 
treatment will add clarity to their tumorigenic potential. However, out of an 
abundance of caution standardised purification and expansion protocols should be 
established, as chromosomal abnormalities are mainly related to culture conditions 
[61]. As part of these considerations, culture conditions with low proliferation rates 
and minimal expansion rates are recommended to minimise the risk of acquired 
chromosomal aberrations [61].  
In conclusion, while the risk from malignant transformation of MSCs has been 
overstated in the past, it will be essential to put stringent quality-control and 
standardisation procedures in place for MSCs to fulfil their potential in clinic 
applications. 
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MSCs and their pro-metastatic activity 
Another issue that arose with MSCs is their potential to promote metastasis 
development in different cancer models [62-64]. In this context, MSCs can induce 
cancer cell dissemination in tumours that normally do not form metastatic lesions, 
whereas in tumours with a high potential to metastasise, MSCs cannot further increase 
the dissemination process [62]. The ability of MSCs to promote tumour metastasis was 
demonstrated in mammary carcinoma mouse models as well as osteosarcoma and 
colorectal cancer in these reports. While the initial results were obtained from cancer 
cells co-implanted with MSCs [63], it was later shown that established tumours could 
also be induced to form metastatic lesions by systemically administered MSCs, of both 
human and murine origin [62].  
Currently, several hypotheses how MSCs increase the metastatic potential of tumour 
cells exist:  
(a) MSCs within the tumour stroma secret soluble factors, e.g. CCL5 (also known as 
RANTES), which increases the metastatic abilities of cancer cells in a paracrine way 
[63]. In this context, it was also shown that tumour-derived osteopontin (OPN) acts 
on MSCs and induces the production and release of CCL5 [65]. CCL5 acting via its 
receptor CCR5 activates AKT/PKB in cancer cells enabling them to survive the 
different steps of the metastatic process and colonise distal organs [66]. However, 
other factors and pathways may exist that can also trigger cancer cell dissemination, 
of which some act in a cell type and context-specific manner and have not yet been 
identified.  
(b) Within the tumour microenvironment, MSCs can differentiate into other stromal 
cell types, such as carcinoma-associated fibroblasts (CAFs). It is thought that this 
differentiation process can be triggered by the interaction of infiltrating MSCs with 
cancer cells within the primary tumour [67, 68]. CAFs are believed to exert their 
biological effect by secreting tumour growth-promoting factors such as growth factors 
and cytokines, as well as extracellular matrix- and angiogenesis-regulating proteins 
that together create a metastasis-promoting microenvironment [69]. Beyond the 
interaction with cancer cells in the primary tumour, CAFs can also affect cancer cells 
after they entered the circulation leading to increased survival of circulating tumour 
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cells if they are paired together with CAFs in heterotypic tumour-stroma cellular 
units, and consequently higher numbers of metastatic lesions [70, 71]. Despite the 
important role of CAFs in the tumour stroma and beyond, not all of them will be MSC-
derived and it remains to be determined whether MSCs actively promote metastasis 
as differentiated CAFs or as pluripotent stem cells. For more details on CAFs and their 
ability to promote cancer metastasis, please refer to other dedicated review articles 
that have been published [72, 73].  
(c) MSCs and their differentiated progeny protect cancer cells from destruction by 
dampening the immune system thereby increasing the likelihood of dissemination 
and formation of metastatic lesions [74, 75]. MSCs are known to suppress immune 
responses by producing immune-modulatory factors such as IDO, PGE2, TGF-L-
10 and NO acting on T- and B-cells [76-78]. Additionally, they can act via activation of 
potent cellular immune-suppressors such as CD4+FOXP3+ or CD8+FOXP3+ 
regulatory T-cells (Tregs) and myeloid-derived regulatory cells including dendritic 
cells (DCregs), monocytes/macrophages (M-MDSCs) and granulocytes (G-MDSCs) 
[79-81]. More details of the intricate and complex cross-talk of MSCs with immune-
modulatory cells are discussed in a review by Koh & Kang [69].  
(d) MSCs can stimulate epithelial-mesenchymal transition (EMT) of cancer cells [82] 
and thereby promote the invasiveness of cancer cells they intact with. EMT is a 
developmental process, in which epithelial cells acquire mesenchymal, fibroblast-like 
characteristics and show decreased intercellular adhesion and increased motility. As 
these are features, important for disseminating tumour cells, it was first hypothesised 
and now has been widely recognised that EMT is also involved in the metastatic 
process [83, 84]. HGF, EGF, PDGF, TGF-and leptin are factors that can be produced 
by MSCs [85-87], which in turn activate a series of EMT-promoting transcription 
factors such ZEB1, ZEB2, Slug, Snail, and Twist as well as other EMT-inducing factors 
such as SERPINE1, MMP-2, and IL-6 [87-90]. Experimentally, a potential role of MSC-
induced EMT has been shown for breast, melanoma, head and neck squamous cell 
carcinoma, ovarian, endometrial, pancreatic, gastric and colon cancer [88, 89, 91-94]. 
Therefore, the induction of EMT might be the mode of action by which MSCs promote 
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metastasis development, but obviously this function might overlap with some of the 
other activities ascribed to them and summarised above.  
In contrast to these observations there are also reports describing a reduction in 
tumour growth even in responses to unmodified MSCs, at least in certain cancer 
models. Such anti-cancer properties were attributed to soluble factors secreted by 
MSCs [95]. However, the overall balance lies with cancer-progression-promoting 
functions of MSCs at this point. Therefore, in the short term MSCs should probably be 
used only after a careful risk-benefit analysis in humans, in particular in clinical cancer 
trials. Furthermore, the therapeutic payload should also target metastasising cells and 
thereby overcome the potential metastasis-promoting activities by stopping 
disseminating cancer cells in their tracks. In the mid-to-long term, the goal is to 
develop and use “safe” re-engineered MSCs that lack the expression of one or more 
pro-metastatic factors (e.g. CCL5, TGF- For this, further investigations in the 
underlying mechanisms and a deeper understanding of the pro-metastatic effect 
would be beneficial in the development of such safer MSCs for the treatment of cancer. 
However, it will also be crucial to investigate whether the deletion of these genes, 
while creating “safe” MSCs, also leads to a loss of tumour tropism and therapeutic 
activity.  
 
The potential impact of MSCs on anti-cancer therapies 
The ability of MSCs to create an immunosuppressive environment can be potentially 
detrimental for their use in cancer therapy. Generally, the effects of anti-cancer 
therapies are thought to be amplified by immune cells attacking tumour cells marked 
and/or damaged by the treatment. Thus, MSCs either delivering the therapy or being 
used in combination with cytotoxic drugs, radiotherapy or biologicals could block or 
diminish this additional effect and limit the overall therapeutic outcome [96, 97]. In 
this context it is important to consider the mode of action of the treatments and what 
type of cell death they trigger. Programmed cell death or apoptosis has regularly been 
called the silent cell death because it does not lead to an immune response [98]. In such 
a context, the immune dampening effects of MSCs should be inconsequential and 
approaches of MSCs delivering bona fide apoptosis inducing agents such as TRAIL 
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should not be affected. However, recent studies have uncovered evidence of paracrine 
signals originating from dying cells [98-100], and in a setting like this, the therapeutic 
success could indeed be reduced. One way to address this potential problem is to 
prime MSCs with TLR4 to render them immune competent [101]. This is based on a 
concept of MSCs being polarised by downstream TLR signalling into two 
homogenously acting phenotypes classified as MSC1 (immune competent) and MSC2 
(immune-suppressive) [102, 103]. Furthermore, the group who characterised the two 
types of MSCs could show that MSC1-based therapy attenuated tumour growth 
whereas MSC2-treatment promoted tumour progression [104]. However, further 
research needs to address whether MSC1-based cell therapies including different 
therapeutic genes can surpass the efficacy of unprimed MSCs.  
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MSCs in preclinical studies and clinical trials 
 
Efficient tumour homing properties will be of importance in MSC-based cancer 
treatments to surmount the limitations of current therapies such as short drug half-
lives and insufficient delivery. The use of an MSC-delivered and continuously 
produced therapeutic agent could help to overcome these hurdles given that sufficient 
numbers of MSCs are indeed recruited to tumour lesions. Efforts in increasing the 
tumour tropism by local irradiation or by overexpressing molecules involved in 
homing of MSCs (e.g. CXCR4, EGFR or artificial receptors targeting tumour-specific 
receptors) have been shown to increase the number of MSCs in the tumour 
microenvironment [105-109]. 
There are various therapeutic transgenes that have been studied and of these 
approaches three have been continuously developed and have reached the stage of 
clinical trials. The first one (TREAT-ME1) uses MSC-delivery of HSV-TK under the 
control of the CCL5 promoter (Fig. 2A) [48]. The preclinical studies demonstrated 
growth reduction of hepatocellular and pancreatic carcinoma and also a reduction in 
metastases [24, 37]. The CCL5 promoter restricts the HSV-TK expression to the tumour 
microenvironment, so side effects can be minimised.  This is based on the fact that 
MSCs infiltrating tumour tissues start producing the chemokine CCL5 upon contact 
with cancer cells [63]. Thus, the CCL5 promoter becomes active and will drive 
therapeutic transgenes that are regulated by it. After cell delivery, the pro-drug 
ganciclovir will be administered, which is phosphorylated and activated by HSV-TK 
and consequently gives rise to cancer cell death. In the TREAT-ME1 trial autologous 
BM-MSCs that are isolated and expanded to passage 1 are used. They are transduced 
with a gamma-retroviral SIN-vector carrying the CCL5-promoter-HSV-TK expression 
cassette [48]. The successful completion of Phase I/II was recently announced. 
The second clinical trial aims to treat women with recurrent ovarian cancer with IFN-
 secreting MSCs. For this study, MSCs are isolated from healthy male donors, and 
genetically engineered MSCs will then be intraperitoneally administered into patients 
(Fig. 2B). The use of IFN- is based on results from a study in the early 2000s that 
showed profound anti-cancer activities in a preclinical melanoma model [45]. IFN- is 
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a cytokine that has been used to treat multiple sclerosis for many years. In cancer 
treatment it is thought to act through indirect immunomodulatory and antiangiogenic 
properties or through direct antiproliferative effects on malignant cells [110]. 
The third clinical approach using MSCs as gene-therapeutic vehicle aims to deliver 
the TNF-related apoptosis-inducing ligand (TRAIL). In this trial (TACTICAL), 
allogeneic MSCs expressing a full-length version of TRAIL (i.e. membrane bound) will 
be used for the treatment of lung cancer (Fig. 2C) [47]. TRAIL is a protein that can bind 
as a ligand to five different receptors, of which two are functional apoptosis-inducing 
receptors, whereas the other three are so called decoy-receptors [111, 112]. It has been 
shown to selectively induce apoptosis in cancer cells and has been clinically tested as 
recombinant protein and TRAIL receptor-targeting agonistic antibodies [113, 114]. 
MSC-delivered TRAIL has been shown to be more potent than these agents and can 
therefore induce cell death in relatively TRAIL resistant cells [115]. Due to its 
promising results in initial preclinical studies, MSC-based TRAIL therapies have been 
continuously improved over the last few years. Firstly, by engineering a soluble form 
of TRAIL (sTRAIL) enabling it to also act on distant cells, which appears to be 
important for a wider anti-cancer effect [116-119]. Secondly, by generating receptor 
specific variants of sTRAIL, which target specifically one of the two apoptosis- 
inducing TRAIL-receptors, and can therefore, overcome resistance [23, 120, 121]. 
Thirdly, MSCs delivering TRAIL have been successfully used in combination 
therapies [20].  
Other approaches to tackle cancer use MSCs to package and deliver drugs like 
Palitaxel and Gemcitabine [118, 122]. In contrast to other studies, in which MSCs 
deliver an enzyme necessary to convert a prodrug into a pharmacologically active 
drug, primed MSCs do not need to be genetically modified. The loaded MSCs release 
their cytotoxic payload packed in exosomes at the sites of tumour or metastatic growth 
[123, 124]. Overall, MSCs can be loaded with a broad spectrum of anti-cancer agents 
[125]. To do so, multiple packaging methods have been described, ranging from silica 
nanorattles [126] to liposomes [127].  All approaches are relying on MSCs as efficient 
carriers. For this very reason, MSCs also play an important role in theranostics, which 
represent recent efforts to combine diagnostics and therapy with a single agent.  In 
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this context, MSCs have been genetically modified to express the sodium iodide 
symporter protein under the control of the CCL5 promoter. The authors demonstrated 
that tumour stroma–targeted iodide led to a significant reduction of growth in a 
metastatic colon cancer model. At the same time, it was possible to monitor the MSC 
biodistribution in vivo by MRI [128]. Another attempt used fluorescent magnetic 
nanoparticle (FMNP)-labelled MSCs to target gastric cancer [129].  
In recent years, a number of studies have noted that the interactions between MSCs 
and human tumour cells mediate the exchange of biological material via exosomes 
[130-132]. Exosomes are small, extracellular membrane‑enclosed vesicles 
encapsulating a variety of molecules, including proteins, DNA, mRNA and miRNAs, 
and are approximately 30-100 nm in size [133]. They have been shown to play diverse 
roles in tumorigenesis, angiogenesis and tumour progression, and have been mostly 
associated with tumour supportive functions [134-137]. However, there are other 
reports that show tumour growth inhibition [138, 139]. While some of these 
discrepancies can be explained by the differences in the tissue of origin of the 
underlying MSCs [140, 141], the exact roles and mechanisms of MSC‑derived 
exosomes in tumour biology remain largely elusive. Notwithstanding, MSC-produced 
exosomes have been tested as part of experimental cell-free therapies for various 
diseases [142], of which some have been in cancer models [137, 139, 143]. In 
conclusion, exosomes might be able to substitute for MSC cell therapy, but their utility 
as a delivery vehicle needs to be further explored and the exact mechanisms of action 
elucidated. 
A further development in the MSC-based delivery technology field, are so called 
nanoghosts (NGs) that are produced from the cytoplasmic membranes of MSCs. MSC 
surface markers are retained on the NGs and they broadly behave like MSCs in 
relation to in vitro and in vivo tumour targeting capabilities [144]. They can be 
produced in different sizes and loaded with a variety of therapeutics using a 
technologically scalable and pharmaceutically applicable process that involves the 
removal of the cytosol and nuclei residues. The loaded therapeutics can range from 
small molecule compounds to membrane-bound factors over-expressed in MSCs prior 
to NG generation and recombinant proteins and DNA constructs. Such MSC-based 
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NGs (MSC-NGs) are seen as a potentially safer alternative to MSCs, as they are not 
associated with the common risks arising from the administration of living 
proliferating cells. In preclinical tests, systemic administration of MSC-NGs loaded 
with recombinant TRAIL demonstrated a marked inhibition of human prostate cancer 
[144]. Furthermore, in a study to also demonstrate the applicability of MSC-NGs for 
gene therapy, loading with a plasmid expressing the hemopexin-like domain (PEX) of 
human matrix metalloprotease-2 gave rise to a significant therapeutic effect both on 
the primary cancer as well as metastatic lesions [145-147]. Thus, it might be possible 
to use MSC-NGs as a tumour cell therapy by proxy in the future. In this context, it is 
of interest that when MSCs were heat-inactivated (HI-MSC), which means they could 
no longer respond to inflammatory signals or secrete immunomodulatory factors, 
they showed the same biodistribution and persistence after infusion in mice with 
ischemic kidney injury [148]. While in contrast to MSCs, HI-MSC lacked the capability 
to suppress T-cell proliferation or induce regulatory B-cell formation, they, like MSCs 
were able to modulate monocyte function in response to lipopolysaccharides. Hence, 
in specific cases, the functions of MSC, in particular the immunomodulatory effects, 
do not depend on their set of secreted factors (secretome) or active cross-talk with 
immune cells, but on recognition of MSC by monocytic cells [148]. 
 
  
14 
 
Outlook and remaining questions  
 
The fate of MSCs in vivo 
In contrast to other diseases [149], for the treatment of cancer it appears necessary for 
MSCs to engraft in the relevant tissues, i.e. primary cancer, dissemination routes (e.g. 
lymphatic system) and metastatic lesions [45]. However, currently, it is not entirely 
clear how exogenously administered MSCs behave in the human body but what we 
know is summarised in Supplementary Table 2. Multiple studies have demonstrated 
the presence of MSCs in the lung, immediately after injection [150-154]. The majority 
of cells are, however, cleared within the first days of treatment [62, 155]. 
Notwithstanding, even after 11 weeks MSCs were still detectable in the lungs, albeit 
at very low numbers [154] and several other tissues [62]. A human study, examining 
autopsy material from patients following MSC therapy, only found a low degree of 
MSC engraftment, and therefore concluded that MSCs exert their function more likely 
through a ‘‘hit and run’’ mechanism rather than through sustained engraftment [59]. 
However, all attempts to detect exogenously administered MSCs in recipients’ organs 
suffer from limitations in relation to the respective detection method and can clearly 
lead to variabilities in the number of detected MSCs [156-158]. An extra level of 
variability can be added by using different sources of MSCs and having cultured these 
cells under different conditions and expansion rates. In this context, it has been shown 
that extensive expansion, which might be necessary for certain transplantation 
regimens, negatively impacts on the homing capabilities of MSCs [159], whereas 
hypoxic culture conditions increased their migratory potential [160]. Furthermore, the 
site of MSC delivery can also influence the biodistribution of MSCs and should 
therefore be considered when designing a study. As it has been shown that 
intravenously delivered MSCs are entrapped in the lung and cleared to the liver and 
spleen within a day, this mode of application is suitable for the treatment of tumours 
like lung cancer, pleural mesothelioma [46] as well as lung and liver metastases [26, 
128]. Furthermore, MSCs could be found in the bone marrow and lymph nodes [62] 
after several weeks, expanding the utility to disseminating disease and those that form 
metastases in the bone such as prostate cancer. Going forward, it will be important to 
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control the different parameters that determine MSC biodistribution and find 
optimised administration routes for different cancer treatment applications. 
 
Are Induced MSCs (iMSCs) the future? 
Even though MSCs can be cultured relatively easily, their life span is finite and it is a 
challenge to expand them to the numbers required for clinical trials, let alone routine 
clinical use in the future. MSCs derived from human induced pluripotent stem cells 
(iPSC) could offer a solution to these issues and become a virtually inexhaustibly, 
autologous source of MSCs [161, 162]. These cells, commonly referred to as iMSCs 
(even though this abbreviation is also used for immune-modulatory MSCs) are 
generated by culturing iPSCs under specific conditions that regularly involve the use 
of TGF- inhibitors (e.g. SB-431542) and extracellular matrix material (e.g. Matrigel) 
[163, 164]. Recently a new method has been described to derive iMSCs directly from 
primary dermal fibroblasts without the need to go via iPSCs. [165]. iMSCs generated 
by these methods have been shown to possess high differentiation efficiency into 
adipocytes, chondrocytes and osteoblasts and to express characteristic MSCs markers. 
Functionally, iMSCs display similar strong immunosuppressive characteristics and 
produce the same range of cytokines as regular MSCs [166]. In the context of MSC-
based cancer treatments it has been shown that iMSCs are tumour-tropic but have 
much less potential to promote tumour progression than bone marrow MSCs.  The 
iMSCs in this study were readily expandable, underwent senescence after prolonged 
culture and did not form teratomas in vivo [167]. These findings suggest that iPSC-
derived MSCs are a potentially safer and better option for therapeutic applications in 
cancer patients. The protocol used in this study is scalable and able to produce the 
substantial number of cells needed for “off-the-shelf” therapies and bioengineering 
applications. 
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Concluding remarks 
MSCs provide a powerful treatment modality for tumours owing to a series of 
beneficial features. However, there are still remaining issues that should be addressed 
and optimised such as the choice of vector and/or therapeutic gene, the optimal route 
of administration, the question whether allogenic cells provide a good and safe source 
or whether they will be replaced by autologous iMSCs in the future. Furthermore, it 
might be possible to derive so called NGs or exosomes from MSCs to avoid many 
problems associated with the administration of viable cells, but more work 
surrounding their use is needed.  
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Figure legends 
 
Fig. 1. Overview of therapeutic transgenes delivered by MSCs in pre-clinical cancer 
studies. 
Transgenes depicted inside the cells are either expressed as intracellular proteins (e.g. 
HSV-TK) or as transmembrane proteins (e.g. full-length TRAIL). Most pre-clinical 
approaches however, target cancer cells by MSCs expressing soluble and secreted 
proteins such as interleukins, interferons, death-ligands (e.g. sTRAIL) or various other 
proteins. Further details, including a detailed reference list, of MSC-based pre-clinical 
studies are provided in Supplementary Table 1. 
 
Fig. 2. Current MSC clinical trials targeting cancer. 
A. Schematic illustration of the TREAT-ME trial. Autologous BM-MSCs from 
patients with advanced, recurrent or metastatic gastrointestinal 
adenocarcinoma are isolated and transduced with a retroviral vector 
containing the HSV-TK gene under the control of the CCL5 promoter. The 
transduced MSCs are administered before Ganciclovir is given to the patient. 
HSV-TK is only expressed when MSCs infiltrate tumour tissues, cross-talk to 
cancer cells and the CCL5 promoter becomes active. The prodrug Ganciclovir 
is then converted to the phosphorylated and active form by HSV-TK. 
B. Overview of a clinical trial using IFN- secreting MSCs for the treatment of 
advanced ovarian cancer. BM-MSCs from male donors are transfected with 
plasmid constructs with an IFN- expression cassette. The resulting IFN--
secreting MSCs are intraperitonially administered. 
C. Summary of the TACTICAL trial for lung cancer. Allogenic BM-MSCs are 
lentivirally transduced to express full-length TRAIL before being administered 
to patients with advanced lung cancer. 
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Abbreviation List  
AAV  adeno-associated virus  
AKT  RAC-alpha serine/threonine-protein kinase 
AT  adipose tissue 
BM  bone marrow 
CAF  carcinoma-associated fibroblast 
CCL5  chemokine (C-C motif) ligand 5 
CCR2  C-C chemokine receptor type 2 
CCR5  C-C chemokine receptor type 5 
CD  cluster of differentiation 
c-Met   tyrosine-protein kinase Met 
CXCR4 C-X-C chemokine receptor type 4 
DCregs dendritic cells 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor 
EMT  epithelial-mesenchymal transition  
FMNP fluorescent magnetic nanoparticle 
G-MDSC granulocytic myeloid derived suppressor cells 
HGF   hepatocyte growth factor 
HI  heat-inactivated 
HLA  human leukocyte antigen 
HMGB1 high mobility group box 1  
HSC  haematopoietic stem cell 
HSV-TK  herpes simplex virus -thymidine kinase 
IDO   indoleamine 2,3-dioxygenase 
IFN-  interferon-beta
L-6  interleukin-6 
L-10  interleukin-10 
iMSC  induced MSC 
iPSC  induced pluripotent stem cells  
ISCT  International Society of Cellular Therapy  
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MCP-1 monocyte chemoattractant protein-1 
MDSC myeloid-derived suppressor cell 
M-MDSC monocytic myeloid-derived suppressor cell 
MMP-2 matrix metalloproteinase-2 
MRI  magnetic resonance imaging 
MSC  mesenchymal stem cell 
NG  nanoghost 
NO   nitric/nitrogen oxide 
OPN  osteopontin 
PDGF  platelet-derived growth factor 
PDGFR platelet-derived growth factor receptor 
PEX  hemopexin-like domain  
PGE2  prostaglandin E2 
PKB  protein kinase B 
RAGE  receptor for advanced glycation endproducts 
RANTES regulated on activation, normal T cell expressed and secreted 
SDF-1  stromal cell-derived factor-1 
SERPINE1 serine proteinase inhibitor E1 
SIN  self-inactivating 
STR  short tandem repeat  
sTRAIL soluble/secreted TRAIL 
TGF- transforming growth factor beta
TLR  Toll-like receptor 
TNF  tumour necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
Tregs  regulatory T-cells 
 UC  umbilical cord 
VEGF   vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
ZEB1  zinc finger E-box binding homeobox 1  
ZEB2  zinc finger E-box binding homeobox 2   
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Supplementary Table1. List of therapeutic transgenes used in MSC-based experimental pre-clinical 
studies. 
Expressed transgene Targeted tumour in pre-clinical 
studies 
IFN-α B16F10, mouse melanoma cells, established as 
lung metastases model [1]. 
IFN-β TRAMP-C2, murine prostate cancer cells, 
established as lung metastases model [2].  
4T1, murine breast cancer cells, established as 
orthotopic mouse model [3]. 
LMeC canine melanoma cells established as 
xenograft model [4].  
B16F10 mouse melanoma xenograft model [5]. 
In combination with IL-18 in a rat intracranial 
glioma model [6]. 
PANC-1, human pancreatic carcinoma cells, 
orthotopically implanted [7]. 
Huh7 hepatocellular carcinoma xenograft 
model [8]. 
IFN-γ H460 human non-small cell lung carcinoma 
model [9]. 
In combination with TRAIL, B16F10 mouse 
melanoma cells in xenograft and metastasis 
models [10].   
IL-12 B16F10, mouse melanoma cells, established as 
lung metastases model [11]. 
B16 mouse melanoma cells, LLC murine Lewis 
lung cancer - and murine HCC hepatoma cells in 
unestablished tumour models [12]. 
B16 melanoma cell xenograft models [13, 14]. 
Hepatoma cell xenograft models [13].  
Ast11.9-2 murine glioma cells implanted into 
mouse brains [15]. 
GL26, mouse glioma cells, implanted into 
mouse brains [16]. 
4T1, murine breast cancer cell xenograft model 
[13, 17]. 
786-O, human renal cell carcinoma cell 
xenograft model [18]. 
TC-1 cervical cancer cells in a xenograft and 
lung metastases model [14]. 
HCa-I and Hepa 1-6 cells in heterotopic murine 
hepatoma models [19]. 
Liver cancer H22 and MethA ascites models 
[20]. 
IL-18 C6 glioma-bearing rat models [21] 
In combination with IFN-β in a rat intracranial 
glioma model [22]. 
CX3CL1 C26 mouse colorectal carcinoma cells, B16F10 
mouse melanoma cells and LLC Lewis lung 
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carcinoma cells established as lung metastases 
model [23]. 
HSV-TK Intracranial 9L rat glioma model [24]. 
9L, rat glioma cell xenograft model [25]. 
Intracranial glioma model [26]. 
In combination with TRAIL, Gli36vIII-FmC, 
human glioblastoma multiforme cells implanted 
into mouse brains [27].   
U-87 glioma cells in an intracranial xenograft 
model [28]. 
Orthotopic PANC02 pancreatic carcinoma 
model [29]. 
Hepatocellular carcinoma xenograft model [30]. 
In combination with dodecameric TRAIL, RENCA 
murine renal carcinoma cells established as 
lung metastases model [31]. 
iNOS Rif-1 fibrosarcoma-bearing mice [32]. 
NK4 C-26, colon cancer cells as lung metastasis 
model [33]. 
MKN45, gastric carcinoma xenograft model 
[34]. 
TSP-1 In combination with sTRAIL, LN229-Fluc-
mCherry cells in an intracranial glioma model 
[35]. 
PEDF U-87 glioma cells in an intracranial xenograft 
model [36]. 
Lewis lung carcinoma cells established as lung 
metastases model [37]. 
CT26 cells in a colorectal peritoneal 
carcinomatosis model [38]. 
Orthotopic model of hepatocellular carcinoma 
[39]. 
Endostatin U87MG-EGFRvIII-driven intracranial xenograft 
model [40]. 
A2780 human ovarian cancer xenograft model 
[41]. 
CT26 cells in a colorectal peritoneal 
carcinomatosis model [42]. 
NIS MDA-MB-231, breast cancer xenograft model 
[43]. 
Huh7, human hepatocellular carcinoma 
xenograft model [44, 45]. 
LS174t, colon cancer liver metastasis model 
[46]. 
TRAIL Primary human-derived TRAIL resistant 
glioblastoma stem cells mouse intracranial 
xenograft model [35, 47].  
U87MG glioma xenografts [48].  
U-87 glioma cells in an intracranial xenograft 
model [49, 50]. 
U87MG intracranial xenograft model [51, 52]. 
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U87-mC-FL tumour model [53]. 
Gli36-EGFRvIII-FD-driven intracranial xenograft 
model [54].  
MK886, orthotopic glioma xenograft model 
[55]. 
Intracranial F98 rat glioma model [56]. 
U87-EGFRvIII glioma cells in an intracranial 
xenograft model [57].   
Gli36vIII and LN229 human glioblastoma 
multiforme intracranial xenograft model [58].   
In combination with HSV-tk, Gli36vIII-FmC, 
human glioblastoma multiforme intracranial 
xenograft [27].   
DAOY and UW426 medulloblastoma cells in an 
intracranial xenograft model [59]. 
MSTO-211H, pleural mesothelioma model [60]. 
MESO, pleural mesothelioma model [61]. 
Tongue squamous cell carcinoma [62]. 
A549 lung cancer xenograft model [63]. 
MDA-MB-231, breast cancer xenograft model 
[64]. 
MDA-MB-231, breast cancer lung metastases 
model [64, 65]. 
MDA-MB-231, orthotopic breast cancer 
xenograft model [66]. 
In combination with HSV-tk, RENCA murine 
renal carcinoma cells established as lung 
metastases model [31]. 
HeLa, cervical cancer xenograft model [67]. 
Malignant fibrous histiocytoma model [68]. 
In combination with IFN-γ, RFP-melanoma cells 
in xenograft and metastasis models [10].   
PancTu1 pancreatic cancer xenograft model 
[69].  
Mia-PaCa2, human pancreatic cancer cells, 
transplanted to the chorioallantoic 
membrane of fertilized eggs hybrid LB chicks 
[70]. 
Colo205 xenograft tumour model [71]. 
HT29 colorectal cancer xenograft model [72].  
DLD-1 colorectal cancer xenograft model [73]. 
HCT116 colorectal cancer xenograft model [74]. 
Orthotopic model of hepatocellular carcinoma 
[75]. 
MHCC97-H hepatocellular carcinoma xenograft 
model [76]. 
TNF A375 melanoma cells in a lung metastases 
model [77]. 
Fused to fusing Tumstatin; PC3 prostate cancer 
xenograft model [78]. 
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SGC-7901, human gastric cancer cells in a 
xenograft model [79]. 
LIGHT Murine gastric cancer models [80]. 
tsFlk-1  Raji, Burkitt's lymphoma cells, subcutaneously 
injected [81]. 
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Supplementary Table2. Biodistribution of MSCs 
MSC type Model Organs in which 
MSCs were 
detected 
Method of 
MSC delivery 
Reference 
autologous hBM-
MSCs 
patients with 
mammary 
carcinoma 
 
blood i.v. [1] 
111In-oxine labelled 
human MSCs 
patients with liver 
cirrhosis 
lungs, liver, 
spleen 
i.v. [2] 
murine MSCs from 
different age 
groups 
transgenic APP/PS1 
Alzheimer’s 
disease mice 
lungs, lymph 
nodes, blood, 
kidney, bone 
marrow, spleen, 
liver, heart, and 
brain cortex  
 
i.v. [3] 
murine umbilical 
cord-derived 
mesenchymal 
stem cells 
carbon 
tetrachloride-
induced acute liver 
injury 
lungs, lymph 
nodes 
i.v. [4] 
human MSCs  
 
hepatocellular 
carcinoma model 
tumour, spleen i.v. [5] 
human umbilical 
cord-derived 
mesenchymal 
stem cells 
spinal cord injury 
model 
spinal cord, 
lungs, liver, 
spleen 
 
i.v. [6] 
hBM-MSCs rat  liver, spleen, 
heart, and lungs 
i.v. [7] 
hBM-MSCs glioma model lungs, liver, 
spleen, brain 
i.v. [8] 
human umbilical 
cord-derived 
mesenchymal 
stem cells, hBM-
MSC, porcine BM-
MSC, rat MSC 
mouse, rat, and 
porcine models 
lungs, heart, 
liver, spleen, 
pancreas, kidney, 
GI tract, femur 
i.v. [9] 
hBM-MSCs, 
murine MSC 
mouse BM, liver, lymph 
nodes, lungs, 
spleen 
i.v. [10] 
MSC-nanoghosts prostate cancer 
model 
tumour, liver i.v.  and i.p. [11] 
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